FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.
What happened
FDA inspected Medical Chemical Corporation's drug manufacturing facility at 19430 Van Ness Avenue, Torrance, from February 12 to 18, 2025. The agency found inadequate identity testing of incoming components, including no methanol testing of ethanol and no diethylene glycol (DEG) or ethylene glycol (EG) testing of glycerin, an unvalidated water system with excessive microbial growth, and quality-unit record oversight failures. FDA also found MED CHEM Tincture Green Soap to be an unapproved new drug and misbranded, and said Tincture Green and Isopropyl Alcohol were not properly listed after being inactivated in January 2024.
What FDA found
The firm did not test each incoming component lot for identity or establish the reliability of supplier certificates of analysis, and it did not test ethanol for methanol or glycerin for DEG/EG.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm lacked adequate written production and process controls and did not validate or properly monitor its water system, which showed excessive microbial growth.
21 CFR 211.100(a)The quality control unit did not ensure adequate batch production and laboratory records.
21 CFR 211.22; 21 CFR 211.188(b); 21 CFR 211.194(a)MED CHEM Tincture Green Soap is an unapproved new drug and is misbranded because it does not meet the requirements for marketing without an approved application.
FD&C Act sections 505(a) and 502(ee) (21 U.S.C. 355(a), 352(ee))Tincture Green and Isopropyl Alcohol were not properly listed because required listing updates or certifications were not made, and FDA inactivated them in January 2024.
FD&C Act section 510(j) and 502(o); 21 CFR Part 207 / 207.57(b)
What FDA wants
FDA asks the firm to provide an independent review of its material system, testing specifications, COA validation, water-system validation and risk assessment, documentation CAPA, and retain test results for methanol and DEG/EG no later than 30 calendar days from the letter. The letter also asks for corrective actions and possible customer notifications or recalls based on risk assessments.
Who should pay attention
- OTC topical drug manufacturers using ethanol, isopropyl alcohol, or glycerin
- brands and distributors buying hand sanitizers or antiseptic products from this firm
- regulatory and quality teams responsible for drug listing and supplier qualification
This is a summary. Read the original letter on fda.gov.